Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 42% Improvement Relative Risk Ventilation 53% Discharge 42% Hospitalization time 5% no CI Sandhu et al. Colchicine for COVID-19 LATE TREATMENT Is late treatment with colchicine beneficial for COVID-19? Prospective study of 112 patients in the USA Lower mortality (p=0.0006) and ventilation (p<0.0001) Sandhu et al., Canadian J. Infectious Diseases a.., doi:10.1155/2020/8865954 Favors colchicine Favors control
A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection
Sandhu et al., Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2020/8865954
Sandhu et al., A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate.., Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2020/8865954
Oct 2020   Source   PDF  
  All Studies   Meta
Prospective cohort study of hospitalized patients in the USA, 34 treated with colchicine, showing lower mortality and intubation with treatment.
risk of death, 41.7% lower, RR 0.58, p < 0.001, treatment 16 of 34 (47.1%), control 63 of 78 (80.8%), NNT 3.0.
risk of mechanical ventilation, 52.9% lower, RR 0.47, p < 0.001, treatment 16 of 34 (47.1%), control 68 of 68 (100.0%), NNT 1.9.
risk of no hospital discharge, 41.7% lower, RR 0.58, p < 0.001, treatment 16 of 34 (47.1%), control 63 of 78 (80.8%), NNT 3.0.
hospitalization time, 4.5% lower, relative time 0.95, treatment 34, control 78.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sandhu et al., 27 Oct 2020, prospective, USA, peer-reviewed, 4 authors, dosage 1.2mg days 1-3, 0.6mg days 4-15.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: Hindawi Canadian Journal of Infectious Diseases and Medical Microbiology Volume 2020, Article ID 8865954, 9 pages Research Article A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection Tegveer Sandhu , Arlene Tieng , Sridhar Chilimuri , and Giovanni Franchin Department of Internal Medicine, BronxCare Health System, Bronx, NY 10457, USA Correspondence should be addressed to Tegveer Sandhu; Received 30 July 2020; Revised 21 September 2020; Accepted 8 October 2020; Published 27 October 2020 Academic Editor: Aim Hoepelman Copyright © 2020 Tegveer Sandhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Colchicine has been used in conditions such as periodic febrile illness, acute pericarditis, and gouty arthritis, all having a common hyperinflammatory response as seen in moderate to severe forms of coronavirus disease 2019 (COVID-19). This project was carried out during the rapid surge of cases in New York City, and the goal was to assess the efficacy of colchicine in treating patients with COVID-19. Methods. Patients admitted to two distinct pulmonary oriented floors of the BronxCare Hospital Center were compared. Patients on one floor were given colchicine in addition to standard of care, while control patients from another floor received only standard of care. Patients who had at least two separate timepoint measurements for at least two out of four serum inflammatory markers (C-reactive protein (CRP), D-dimer, ferritin, or lactate dehydrogenase (LDH)) were selected for the final comprehensive analysis. Results. An initial analysis performed on all patients, irrespective of the availability of two timepoint inflammatory markers, revealed a lower mortality (49.1% versus 72.9%, P � 0.002), a lower percentage of intubations (52.8% versus 73.6%, P � 0.006), and a higher discharge rate (50.9% versus 27.1%, P � 0.002), in the patients who received colchicine. Patients in the final comprehensive analysis groups (34 in the colchicine group and 78 in the control group) had a similar prevalence of comorbid medical conditions, except for renal failure, which was higher in the control group (65.3% versus 35.2%, P � 0.015). HTN (71.8% versus 52.9%, P � 0.053) and DM (51.3% versus 32.4%, P � 0.064) were also more prevalent in the control group, although the difference was not statistically significant. Patients who received colchicine had a lower mortality than the control group (47.1% versus 80.8%, P � 0.0003), lower rate of intubations (47.1% versus 87.2%, P < 0.0001), and a higher discharge rate (52.9% versus 19.2%, P � 0.0003). Patients in the colchicine group also showed a more significant decrease in inflammatory markers for D-dimer (P � 0.037), CRP (P � 0.014), and ferritin (P � 0.012). Conclusions. Our study demonstrates that colchicine improved outcomes in patients with COVID-19 receiving standard of care therapy. Future randomized, placebo-controlled clinical trials to assess the potential benefit of colchicine in COVID-19 are warranted.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop